Alnylam Pharmaceuticals Inc. (ALNY) Downgraded by Needham & Company LLC
Needham & Company LLC lowered shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) to a buy rating in a report issued on Thursday morning. Needham & Company LLC currently has $137.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $152.00.
Other equities analysts also recently issued research reports about the stock. Cowen and Company reissued a buy rating and issued a $150.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 5th. Credit Suisse Group AG reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, June 12th. FBR & Co reissued a buy rating on shares of Alnylam Pharmaceuticals in a research note on Friday, June 10th. Finally, Jefferies Group reissued a buy rating and issued a $80.00 price objective (down previously from $119.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, June 8th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Alnylam Pharmaceuticals currently has a consensus rating of Buy and an average price target of $80.88.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 35.52 on Thursday. The stock’s market capitalization is $3.04 billion. Alnylam Pharmaceuticals has a 1-year low of $33.16 and a 1-year high of $110.75. The stock has a 50 day moving average price of $69.62 and a 200-day moving average price of $65.95.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm earned $8.70 million during the quarter, compared to the consensus estimate of $8.09 million. During the same quarter in the previous year, the firm posted ($0.85) earnings per share. The company’s revenue was up .2% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals will post ($4.68) EPS for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at $9,604,200.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.00% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of ALNY. Dodge & Cox acquired a new stake in Alnylam Pharmaceuticals during the second quarter valued at approximately $139,650,000. Wellington Management Group LLP increased its position in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares during the period. Bridger Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter worth $50,041,000. Slate Path Capital LP increased its position in shares of Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares during the period. Finally, Deerfield Management Co. purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter worth $18,645,000. 85.96% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.